The Clinical/Tissue Core has been an important component of the CSIBD since its inception, serving as the nexus between investigators exploring the etiology and pathophysiology of the inflammatory bowel diseases and patients with these conditions. The Clinical/Tissue Core has supported the needs of researchers both within and external to the CSIBD through a number of highly organized efforts designed to facilitate connections between bench top and clinic, specifically the IBD and control patient base within the MGH Crohn's &Colitis Center and the gastroenterology practice at Massachusetts General Hospital. To date, these efforts have included 1) a clinical database of patients with inflammatory bowel disease seen at the Massachusetts General Hospital, 2) tissue samples, 3) tissue sections, 4) a serum bank, 5) immortalized lymphocytes from IBD probands, as well as their affected and unaffected 1*'degree relatives and 6) clinical research support. These resources have evolved over the duration of the CSIBD as both needs and capabilities have evolved, and will continue to change and adapt over the next 5 years of funding. Within the next 1 to 2 years it is anticipated that the genetic architecture underpinning the inflammatory bowel diseases largely will have been elucidated, with GWAS studies already having identified loci with even modest effect sizes (odds ratios as low as 1.2) in Crohn's disease and ulcerative colitis following a similar trajectory of discovery, although lagging by 1 to 2 years. We anticipate that this remarkable accomplishment will drive the need to revise the focus of the Clinical/Tissue Core in the coming funding period.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK043351-24
Application #
8583314
Study Section
Special Emphasis Panel (ZDK1-GRB-8)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
24
Fiscal Year
2014
Total Cost
$92,982
Indirect Cost
$41,685
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Ma, Wenjie; Jovani, Manol; Liu, Po-Hong et al. (2018) Association Between Obesity and Weight Change and Risk of Diverticulitis in Women. Gastroenterology 155:58-66.e4
Moretti, Francesca; Bergman, Phil; Dodgson, Stacie et al. (2018) TMEM41B is a novel regulator of autophagy and lipid mobilization. EMBO Rep 19:
Kim, Young-In; Song, Joo-Hye; Ko, Hyun-Jeong et al. (2018) CX3CR1+ Macrophages and CD8+ T Cells Control Intestinal IgA Production. J Immunol 201:1287-1294
DeBoever, Christopher; Tanigawa, Yosuke; Lindholm, Malene E et al. (2018) Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. Nat Commun 9:1612
Domman, Daryl; Chowdhury, Fahima; Khan, Ashraful I et al. (2018) Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. Nat Genet 50:951-955
Rivas, Manuel A; Avila, Brandon E; Koskela, Jukka et al. (2018) Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genet 14:e1007329
Simon, Tracey G; King, Lindsay Y; Chong, Dawn Q et al. (2018) Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 67:1797-1806
Borren, Nienke Z; Conway, Grace; Garber, John J et al. (2018) Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. J Crohns Colitis 12:525-531
Qu, Chen; Zheng, Dandan; Li, Sai et al. (2018) Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology :
Imhann, Floris; Vich Vila, Arnau; Bonder, Marc Jan et al. (2018) Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 67:108-119

Showing the most recent 10 out of 1166 publications